Find information on Industry Analysis Report

Posts tagged ‘pharmaceutical’

Report on Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2011-2021

What are the commercial prospects for pharmaceutical anti-counterfeiting technology? Our new report shows you that industry and market’s revenue potential from 2011 to 2021.

There, you will assess anti-counterfeiting technologies, seeing trends and opportunities. We aim to save you time and aid your decisions through our research, analysis and discussions.

Our report shows you revenue prospects for pharma anti-counterfeiting technologies at total world, submarket and national levels to 2021. We discuss the anti-counterfeiting activities of companies such as Pfizer, J&J, GSK, Sanofi-Aventis, Novartis and AstraZeneca.

We also discuss the activities and potential of anti-counterfeiting specialists, such as NanoGuardian, Ahura Scientific, TruTag Technologies, Colorcon, Authentix, 3M, Cortegra and Covectra.
Our study forecasts revenues for radio frequency identification (RFID), pharmaceutical taggant, hologram/OVD, security ink and watermark technologies to 2021. You will see their market potentials.
Which pharma anti-counterfeiting technologies and national markets will provide the best opportunities from 2011 to 2021? What effects will governmental policies have? Our work gives answers you need.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.
Industry and market analysis to help your work – so you won’t be left behind

Our report gives you revenue forecasts, growth rates and market shares. We also provide a SWOT/STEP analysis, review of companies and product developments, and opinions from our survey.
We include 67 tables and charts and three research interviews (shown in the accompanying lists). Our study helps you to understand pharma anti-counterfeiting activities this decade.
Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:
• You will receive hard data for the pharmaceutical anti-counterfeiting industry and market from 2010 to 2021
• You will discover revenue forecasting for the overall world market to 2021
• You will see revenue predictions for leading technologies – RFID, taggants, holograms/OVDs, security inks and watermarks – to 2021
• You will assess anti-counterfeiting needs at world and regional level
• You will find revenue predictions for leading geographical markets to 2021 (US, UK, Germany, France, Japan, Italy, Canada, Spain, China and India)
• You will assess the implications of government mandates for product serialisation, seeing how these will affect the activities of pharma companies
• You will assess leading companies in pharma anti-counterfeiting, discovering their activities, potential and commercial outlooks for the future
• You will examine research and development, as well as up-and-coming technologies for tackling drug counterfeiting
• You will investigate competition and opportunities that will influence revenues
• You will see what will stimulate and restrain the industry and market
• You will analyse opportunities for established companies and those seeking to enter the anti-counterfeiting technologies market
• You will view opinion from our survey, including full interview transcripts.

That mix of quantitative and qualitative market analysis sets our report apart. Our analysis helps you to stay ahead in commercial knowledge.
Order our report now to gain industry and market information you need
Our report can benefit everybody interested in pharmaceutical anti-counterfeiting technologies. We give predictions and answers you need. Don’t miss out – please order our report now.

For more information kindly visit :
Report on Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2011-2021


Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Follow us on twitter:!/Sandhya3B


Research Report on World Medical Market Forecasts

The global market for medical equipment and supplies as defined in this report is valued at US$307.7 billion in 2012, equal to just under US$50 per capita. Several years of rapid growth came to a halt amid the economic downturn towards the end of 2008 and into 2009. Many countries experienced a slowdown in the market in 2009, with especially poor performance in the USA and Europe. Much of the world has seen a swift return to growth in 2010 and 2011, however, with the major exception of the Eurozone, which continues to perform relatively poorly.

The CAGR for the 2007-2011 period was 7.9%, although this masks the major reduction in growth which occurred in 2009 and 2010. Market growth resumed in 2011, although it will not be quite as rapid as before the economic downturn. Espicom projects that the total market will rise to US$434.4 billion by 2017, equal to just underUS$67 per capita and a CAGR for the 2012-17 period of 7.1%. Some of the best prospects for growth will be in the developing markets of Asia, Latin America and Central/Eastern Europe, while traditional Western markets represent more steady performers.

Use this new report to easily answer questions such as:
Which Asian countries offer the best opportunities for market growth and in which sectors?
Which Eurozone medical sector is set to exceed US$32 billion and a 2012-17 CAGR of 7%?
What are the prospects for MRI in Latin America and which countries offer the best opportunities?
How did the Chinese orthopaedic sector fare in 2011 and what are its prospects to 2017?

This important business evaluation provides:
Growth forecasts to 2017 for 86 markets – 20 more than last edition
Comparative data on a regional and global basis
Rankings by key indicators allow “at a glance” benchmarking of countries
Detailed information on each market
This report is available in pdf or print formats with Espicom Interactive web access for all customers
Practical value as all tables and graphs can be easily exported to be included in your own reports and data sets

This new report provides detailed market forecasts
Worldwide Medical Markets Forecasts to 2017 is essential for business forecasters, marketing planners and the investment community. Anyone, in fact, who needs to understand the future outlook for the dynamic medical device and equipment industry.

In 416 information-packed pages the report provides thousands of market projections, rankings and comparisons.

Provided with global, regional and national views
A global overview of key rankings

Six regional sections allow comparative assessment of countries within a geographic region:
Western Europe
Central & Eastern Europe
Middle East/Africa
Sub Saharan Africa
Individual markets to provide detail and forecasts at a national level

For more information kindly visit :
Research Report on World Medical Market Forecasts


Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Follow us on twitter:!/Sandhya3B!/bharatbook

Research Report on Understanding Japan’s Regional Health Markets

The popular view of the Japanese health market contains much myth and assumption. Despite long term economic woes and the impact of the tsunami in March 2011, Japan’s position as the world’s 2nd biggest market by health expenditure represents a technologically advanced country self sufficient in meeting the needs of its health system and population. But will that be true in the future?

Any assessment of Japan must consider the impact of recent natural disasters, and the economic and demographic challenges that are influencing the development of the health market.
How is wealth distributed regionally?
Which regions produce the highest levels of GDP and does that correlate to increased health spending?
How is Japan’s increasingly elderly population distributed across the country?
How is healthcare delivered?

Identifying opportunities in Japan’s health economy requires being able to see the economic performance and health infrastructure at a regional as well as the national level.

Rich in statistics, charts and maps, this new 194-page report from Espicom Understanding Japan’s Regional Health Markets takes you further into understanding the national and regional health environments.

Japan’s population of 121 million is ageing fast. Their distribution, however, is inconsistent with an urban/rural divide opening up: how is this impacting regional health economies, which are most affected and what are the implications for medical product suppliers?

Japan is an archipelago consisting of 6,852 islands, the 4 largest of which account for 97% of the country’s 377,835 land area.
The population of Japan totalled 128.1 million in 2010. The population had been in decline since 2007, but 2010 marked a return to growth, with an increase of 546,000.
The country is organised into 8 districts which are further subdivided into 47 administrative prefectures. Economic and health data is provided in the report to these levels.

All developed nations to a greater or lesser degree are experiencing an increase in the number of elderly as a % of their population, but no other country is in Japan’s position.

While the proportion of elderly people in Japan has been steadily rising, a falling birth rate has seen the under fifteen age group decline. In 1990 there were 22.5 million aged 0-14 years. By 2010, that figure had fallen to 16.8 million people or 13.2% of the total population.

Correspondingly, the number of people in the over 65 age group has risen steadily, increasing over 20 years from 14.9 million to 29.3 million – or 23.1%.

This is a long term trend. It is estimated that by 2060, over 40% of the population will be aged over 65 years, while people of working age who will bear the financial burden of caring for the elderly, will only represent under half of the population.

In addition, there has been considerable migration to urban areas by younger Japanese attracted to employment prospects, so much so that the aged population in some rural regions is already creating a notable disparity in health spending.

For more information kindly visit :
Research Report on Understanding Japan’s Regional Health Markets


Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Follow us on twitter:!/Sandhya3B!/bharatbook

Research Report on The World Pharmaceutical Markets

The World Pharmaceutical Market Fact Book 2012 is the ideal companion in today’s challenging pharmaceutical market environment. The need to understand world pharmaceutical marketplaces, and be able to answer quickly those questions that arise daily, is essential. That is why this current and comprehensive source of key market
statistics is an invaluable aid for every pharmaceutical industry executive.

Proven and reliable
Published by Espicom, for over 30 years experts in the healthcare market field, the 350-page Fact Book brings together a range of often difficult to source information in one
single, convenient and comprehensive publication. Keep it near to you at all times.

The World Pharmaceutical Markets Fact Book 2012 quickly answers key market questions
Which country spends most on pharmaceuticals as a % of GDP?
How are the economic downturn and currency fluctuations affecting expenditure in key markets?
Which pharmaceutical sectors are growing the fastest and where?
How does the Brazilian market compare with Mexico and Argentina in terms of total health expenditure?
What demographic development is affecting the market in Central and Eastern Europe?
What have been the key trends affecting pharmaceutical companies in leading emerging markets such as India, China, Brazil and Russia?

Which other business reference provides…
Key economic, demographic and health statistics on 66 markets around the world
Five years of historical data for markets, GDP & healthcare spending,demographics and healthcare statistics
World/regional overviews plus statistics on individual countries
Over 500 tables and charts
PDF format with Espicom Interactive online access included included in the price. Print option available

Comprehensive Contents
World Overview
Pharmaceutical market (actual and per capita)
Trade in pharmaceutical markets
Economic data and health expenditure
Healthcare data
– Hospital and beds
– Admissions and surgical procedures
– Physicians, nurses, pharmacists and dentists

Regional Overviews
The report provides 5 regional overviews for:
Central/Eastern Europe
Middle East/Africa
Western Europe

Which provide data on:
Market data by product sector
Trade data
Economic data
Health expenditure
Healthcare data
Hospital and beds
Admissions and surgical procedures
Physicians, nurses, pharmacists and dentists

Key facts and figures for 66 markets:
Market Data: 2006-2011

Actual and Per Capita
Trade Data: 2006-2011
Imports/Import growth rate
Exports/Export growth rate

Economic Data: 2006-2011
Health expenditure (US$ billions)
Health expenditure per capita (US$)
Health expenditure as a % of GDP
Public health expenditure as a % of the total

Demographic Data: 2006-2011
Population growth
% population aged 65+
Live births per ’000 population
Deaths per ’000 population
Infant mortality per ‘000 live births
Life expectancy for males/females

Healthcare Data: 2006-2011
Hospitals (public and private)
Hospital beds
Beds per ‘000 population
Inpatient admissions
Inpatient admissions per ‘000 population
Average length of stay (days)
Surgical procedures (‘000’s)
Outpatient visits
Outpatient visits per ‘000 population
Nurses per ‘000 population
Physicians per ‘000 population
Dentists per ‘000 population
Pharmacists per ‘000 population

For more information kindly visit :
Research Report on The World Pharmaceutical Markets


Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Follow us on twitter:!/Sandhya3B!/bharatbook

Research Report on The Global Advanced Wound Care Market

A changing industry landscape
Mergers and acquisitions have always played a key role in the advanced wound care industry and have enabled the market leaders to expand their technology to address new sections of the market and provide access to new technologies. But things are hotting up. Smith & Nephew continues to add to its portfolio with the acquisition in May 2012 of Kalypto Medical while pharmaceutical companies flex their financial muscle: Shire purchased BioHealing in June 2011 while Sanofi’s purchase of Genzyme in April 2011 has introduced the new Sanofi Biosurgery division.

Private equity gets more involved
The headline acquisition of the NPWT leading company KCI by the APAX consortium is just the latest of a string of private equity transactions. Nordic Capital and Avista Capital Partners purchased ConvaTec in August 2008, Systagenix was formed in December 2008 through One Equity Partners’ purchase of Ethicon Professional Wound Care, and Investor AB took full control of Mölnlycke in late 2010.

Biologics: the growth sector of the future?
With price pressures in the NPWT sector and low prices driven by high competition in the Moist Dressings sector, the spotlight has been thrown on Biologics. While all sectors are expected to return to stronger annual growth, only the biologics sector is expected to maintain double digit growth from 2015 onwards as products currently in development are launched.

Key statistics and forecasts provide a real insight to the future of this critical device sector

Wound Care Market
Global Wound Care Market by Product Type, 2011
Professional Wound Care Market by Product Type, 2011

Advanced Wound Care Market Competitors
Select Manufacturers’ Wound Care Sales, 2005-2011 (US$ million)
International Manufacturers’ Wound Care Sales, 2005-2011
Advanced Wound Care Market Shares, 2011
Advanced Wound Care Acquisitions, 2008-2011

Wound Care Market Dynamics
Professional Wound Care Market by Product Type, 2007-2011 (US$ million)
Professional Wound Care Market Forecast, 2012-2017 (US$ million)
Global Wound Care Market Growth by Product, 2012-2017 (%)

Regional Perspective
Advanced Wound Care Market by Region and Growth by Region, 2012-2017 (US$ million)
US, European and Rest of the World Markets by Major Product Type, 2011

More Information…
What this report will give you…
Extensive competitive comparisons and evaluation of 109 major and emerging companies
Market share for leading companies
Growth forecasts and market share to 2017 by product area and geographical region

Covering all major areas including…
Device-based advanced wound care
Negative Pressure Wound Therapy
Electrical Stimulation
Extracorporeal Shock Wave Therapy
Other Wound Care Devices

Moist wound care
Hydrocolloid Dressings
Foam Dressings
Composite Dressings
Activated Charcoal Dressings
Transparent Film Dressings
Antimicrobial Dressings
Silver Dressings
Honey Dressings
Iodine-based Dressings
PHMB Antimicrobial Dressings

Collagen-Based Wound Care Products
Skin Substitutes
Growth Factors
Cell-Based Therapies
Other Biologic Products
Enzymatic Debriding Agents

Answering key questions…
What next for Kinetic Concepts after its litigation troubles?
What % of the European market will moist dressings account for in 2017?
Who’s developing products in the skin substitution market?
Who’s partnering whom, and on what?
Which are the companies and technologies to watch?

For more information kindly visit :
Research Report on The Global Advanced Wound Care Market


Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Follow us on twitter:!/Sandhya3B!/bharatbook

Latest Guide to Chinese Pharmaceutical GMP Regulations

China possesses a fourth population in the world and has one of the largest drug markets round the world. By 2011, sales on the Chinese drug market have reached RMB 1550 billion (about US$246 billion), an increase of 7.08 fold over 2000 level. A series of factors, such as an increasingly ageing population, accelerating growth of urban population as well as expansion of healthcare covering urban and rural will grow the Chinese drug market with a growth rate over 25 percent per annum in next three years. China is expected to become the second largest drug market in the world by 2015.

Since the reform and open door policy implemented by Chinese authorities in the late 1970s, the door of the Chinese drug market began opening up to the world step by step, which not only gave a fillip to the imported drugs from overseas pharmaceutical manufacturers but also attracted overseas investors to establish the foreign investment enterprises, including “Sino-foreign equity joint ventures (EJV)”, “Sino—foreign cooperative joint ventures (CJV)” and “wholly foreign-owned enterprises (WFOE)” in China. Since the 1980s, thousands of foreign pharmaceutical companies have entered the Chinese drug market. Today, multinational pharmaceutical companies have over 1140 active joint ventures and foreign-owned enterprises in China and most giants of global pharmaceutical industry have a Chinese presence, including AstraZeneca, Pfizer, Roche, Novartis, Merck & Co, Eli Lilly & Company, GlaxoSmithKline and Johnson & Johnson. By 2011, sales of drugs manufactured and produced by the foreign-funded pharmaceutical manufacturers and producers in China have shared over one fourth on the Chinese drug market. As China joins the World Trade Organization (WTO) and integrates more completely into the global economy, it will further open the door to a lucrative drug market for foreign-funded pharmaceutical companies, and multinational pharmaceutical companies. More and more overseas pharmaceutical manufacturers and producers expect to enter such drug market and seize a larger part of such drug market.

To enter such a lucrative drug market, the overseas pharmaceutical manufacturers and producers must conform to Chinese Good Manufacturing Practice (GMP) regulations for pharmaceuticals. Therefore, a comprehensive and thorough knowledge of the latest Chinese Pharmaceutical GMP regulations has been become an essential prerequisite for overseas pharmaceutical manufacturers and producers to achieve a successful entry into the Chinese drug market, so more and more overseas pharmaceutical companies and multinational pharmaceutical companies, and their senior executive officers engaging in regulatory affairs expect to understand the latest Chinese Pharmaceutical GMP regulations.

The Chinese health authorities, the Ministry of Health (MOH) issued the latest Good Manufacturing Practice for Drugs (2010 Revision), which came into effect as of March 1, 2011, after five years of amendments and two rounds of public consultation. Since its first promulgation in 1988, Chinese Good Manufacturing Practice for Drugs (GMP) has experienced two amendments in 1992 and 1998 respectively. The latest version of GMP follows up the main principles of WHO GMP, adopting advanced international experiences and in light of the actual conditions of China. The latest version of GMP consists of 14 chapters and 313 articles. The Chinese pharmaceutical authorities, the Sate Food and Drug Administration (SFDA) issued five documents as annexes of the latest GMP, that is, Good Manufacturing Practice for Sterile Pharmaceutical Products, Good Manufacturing Practice for Active Pharmaceutical Ingredients, Good Manufacturing Practice for Biological Products, Good Manufacturing Practice for Blood Products, and Good Manufacturing Practice for Traditional Chinese Medicine Preparations, also came into effect as of the same time with the latest version of GMP.

For more information kindly visit :
Latest Guide to Chinese Pharmaceutical GMP Regulations


Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Follow us on twitter:!/Sandhya3B
Our Blogs:

Gammagard Liquid – Alzheimer’s Disease

Gammagard Liquid Alzheimer’s disease market offers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2022). Pharmaceutical market report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData’s team of industry experts.


  1. Therapy area profile including patient population for the US and EU5 (six major markets)
  2. Market analysis and review of Gammagard Liquid including sales data
  3. Qualitative and quantitative assessment of market space
  4. Analysis of the industry trends, drivers and restraints shaping and defining the markets
  5. In-depth analysis of Gammagard Liquid including efficacy, safety, pricing, competition and other details which influence its sales potential
  6. Global sales forecast for 2014-2022 for Gammagard Liquid

Reasons to buy Gammagard Liquid market Reports:

  1. Understand and capitalize by identifying products that are most likely to ensure a robust return
  2. Stay ahead of competition by understanding the changing competitive landscape
  3. Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  4. Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
  5. Examine the historical sales performance of a drug in seven major market

Tag Cloud